Recent Updates
Recently added Catalysts
ARWR Positive Sentiment Score: 85/100

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

Friday, May 1, 2026 1 min read
Key Takeaway: Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration for REDEMPLO® (plozasiran), a new treatment for adults with familial chylomicronemia syndrome (FCS). This approval allows the drug to be used as an adjunct to diet to help reduce triglyceride levels in patients who have not responded adequately to standard therapies. The move is expected to improve access to treatment for patients suffering from this rare condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval of REDEMPLO® expands treatment options for patients.
  • Addresses a significant unmet medical need in FCS.
  • Enhances global access to innovative therapies.

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can

Frequently Asked Questions

What is REDEMPLO® used for?

REDEMPLO® is used to reduce triglyceride levels in adults with familial chylomicronemia syndrome.

Who approved REDEMPLO® in Australia?

The Australian Therapeutic Goods Administration (TGA) approved REDEMPLO®.

What condition does REDEMPLO® target?

REDEMPLO® targets familial chylomicronemia syndrome (FCS), a rare disease.

How does REDEMPLO® help patients?

It serves as an adjunct to diet for patients with inadequate response to standard therapies.

Tags: ARWR Viatris Investor Conferences Healthcare Arrowhead Pharmaceuticals plozasiran familial chylomicronemia syndrome TGA approval triglyceride levels
Last updated: May 1, 2026